Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MMS to support IGY Life Sciences in advancing Covid-19 antibody candidate
According to IGY Life Sciences, the partnership with the clinical data and regulatory expert will focus on the nasal spray application of IgY-110, which it expects to be
According to IGY Life Sciences, the partnership with the clinical data and regulatory expert will focus on the nasal spray application of IgY-110, which it expects to be
This designation is given to medications with the potential to treat rare conditions — those that affect fewer than 200,000 people in the U.S. Benefits include exemption from
The US-Dutch collaboration will focus on advancing 47D11, a fully human, neutralising antibody therapeutic candidate. Discovery of the antibody was reported last month by Utrecht University, Erasmus Medical
The clinical data were presented at a late-breaking session at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) International Congress being held as a virtual event on
According to Janssen, the subcutaneous formulation of daratumumab is administered as a fixed dose, which considerably brings down treatment time, from hours to nearly three to five minutes,
New institutional investors and family offices participated in the financing alongside original commitments from founding investors MPM Capital and F2 Ventures. Following the completion of the fundraising, Tim
Guselkumab is currently not licensed for the treatment of PsA and is undergoing evaluation for this use by the European Medicines Agency (EMA). Data from the two studies
The approval of Sarclisa and pom-dex combination is for people who had at least two prior therapies including lenalidomide and a proteasome inhibitor and have shown disease progression
True North met both primary endpoints, demonstrating highly statistically significant (p-value < 0.0001) results for induction of clinical remission at Week 10 and in maintenance at Week 52.
The FDA has assigned the application standard review and a Prescription Drug User Fee Act target action date of March 31, 2021. The FDA also indicated that they